Intellia Thera CS (NTLA)

$9.59 +0.17 (1.80%)
Market Cap 1.09B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 1,450,600
Avg Vol 7,248,650
Day's Range N/A - N/A
Shares Out 115.83M
Stochastic %K 77%
Beta 2.13
Analysts Sell
Price Target $22.07

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
1iquid
1iquid Dec. 25 at 3:16 AM
💎 Liquid® Live Actionable Trade Asset: $NTLA Contracts: $NTLA January 15, 2027 $10 Calls Scale in: $3.40- $4.15 Scale out: $13.21-$22.65 Profit Potential : 303% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
TheWolfOfWaterdown
TheWolfOfWaterdown Dec. 24 at 6:41 PM
$NTLA If the ATTR and HAE program both make it to market this should easily be a 5-10 billion dollar valuation based off the proven technology/platform alone. Gene editing will be a game changer
0 · Reply
VVDB
VVDB Dec. 24 at 5:57 PM
$NTLA Bullish! https://youtu.be/Z1EhAyIM7eU?si=eUh390RXflrazggf
0 · Reply
Publicola29
Publicola29 Dec. 24 at 2:33 PM
$NTLA loaded up going to 50
0 · Reply
TheSimulacra
TheSimulacra Dec. 24 at 12:20 PM
$NTLA Investor conviction will hinge on whether operational decisions reinforce credibility with the market. Delays or dilution could materially reshape the risk profile.
0 · Reply
VVDB
VVDB Dec. 24 at 2:26 AM
$NTLA Why ARK Bought 180K NTLA Shares – What Retail Investors Must Know! https://www.youtube.com/watch?v=Z1EhAyIM7eU
0 · Reply
VVDB
VVDB Dec. 24 at 1:38 AM
$NTLA Bullish! https://youtu.be/hwTSgFpWzQ8?si=zx7JSQrn0K93H-JX
0 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 6:04 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Bulls volume on $PCSA $MOVE.X $XTKG $NTLA
0 · Reply
free2dream
free2dream Dec. 23 at 3:45 PM
$LITE watching the time sales closely. There is an institutional whale buying, doesnt want to retail to see ! Load up before this gaps up ! Any day now. THIS IS 10X your money $XBI $LABU $MRNA $NTLA
1 · Reply
GorillaofWallStreet
GorillaofWallStreet Dec. 23 at 12:54 PM
$NTLA Cathy Woods bought over 180,000 shares of NTLA yesterday.
1 · Reply
Latest News on NTLA
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 5, 2025, 4:01 PM EST - 19 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Short List — Top 10 Most Shorted Stocks Right Now

Nov 26, 2025, 11:34 AM EST - 4 weeks ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR CMBM HIMS HTZ LCID REPL SOC

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 6 weeks ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 6 weeks ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 5:46 AM EST - 6 weeks ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 2 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 11:17 AM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 2 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Oct 24, 2025, 8:15 AM EDT - 2 months ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 1:57 PM EDT - 3 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 3 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 19, 2025, 2:31 PM EDT - 3 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 4 months ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 4 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 4 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 5 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 5 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 5 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 6 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 7 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 7 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 7 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 8 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 8 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 8 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 8 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 9 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 9 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

1iquid
1iquid Dec. 25 at 3:16 AM
💎 Liquid® Live Actionable Trade Asset: $NTLA Contracts: $NTLA January 15, 2027 $10 Calls Scale in: $3.40- $4.15 Scale out: $13.21-$22.65 Profit Potential : 303% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
TheWolfOfWaterdown
TheWolfOfWaterdown Dec. 24 at 6:41 PM
$NTLA If the ATTR and HAE program both make it to market this should easily be a 5-10 billion dollar valuation based off the proven technology/platform alone. Gene editing will be a game changer
0 · Reply
VVDB
VVDB Dec. 24 at 5:57 PM
$NTLA Bullish! https://youtu.be/Z1EhAyIM7eU?si=eUh390RXflrazggf
0 · Reply
Publicola29
Publicola29 Dec. 24 at 2:33 PM
$NTLA loaded up going to 50
0 · Reply
TheSimulacra
TheSimulacra Dec. 24 at 12:20 PM
$NTLA Investor conviction will hinge on whether operational decisions reinforce credibility with the market. Delays or dilution could materially reshape the risk profile.
0 · Reply
VVDB
VVDB Dec. 24 at 2:26 AM
$NTLA Why ARK Bought 180K NTLA Shares – What Retail Investors Must Know! https://www.youtube.com/watch?v=Z1EhAyIM7eU
0 · Reply
VVDB
VVDB Dec. 24 at 1:38 AM
$NTLA Bullish! https://youtu.be/hwTSgFpWzQ8?si=zx7JSQrn0K93H-JX
0 · Reply
FullPorrtDipz
FullPorrtDipz Dec. 23 at 6:04 PM
If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Bulls volume on $PCSA $MOVE.X $XTKG $NTLA
0 · Reply
free2dream
free2dream Dec. 23 at 3:45 PM
$LITE watching the time sales closely. There is an institutional whale buying, doesnt want to retail to see ! Load up before this gaps up ! Any day now. THIS IS 10X your money $XBI $LABU $MRNA $NTLA
1 · Reply
GorillaofWallStreet
GorillaofWallStreet Dec. 23 at 12:54 PM
$NTLA Cathy Woods bought over 180,000 shares of NTLA yesterday.
1 · Reply
wrengler4
wrengler4 Dec. 23 at 11:04 AM
$PLTR she had to, margin from her fcuk up at $NTLA .
1 · Reply
PMD777
PMD777 Dec. 23 at 12:22 AM
$NTLA can we get $10 mañana?
0 · Reply
wrengler4
wrengler4 Dec. 22 at 11:51 PM
$NTLA they said that at $DJT AS WELL, AND GUES WHAT NOTHING AND HERE MORE OF THE SAME…NOTHING AND TO MERGER TO BAIL LEONARD
1 · Reply
Letsinvest2024
Letsinvest2024 Dec. 22 at 7:20 PM
$IOVA is 2026 our year? $VKTX $NTLA $PRME
2 · Reply
0x126
0x126 Dec. 22 at 6:35 PM
$NTLA
1 · Reply
FemaleGermanInvestor
FemaleGermanInvestor Dec. 22 at 5:49 PM
$NTLA there is no resistance after $10
0 · Reply
vanguard100
vanguard100 Dec. 22 at 4:33 PM
$NTLA Like the SI here...can pop imo...on watch...
0 · Reply
betrump
betrump Dec. 22 at 4:25 PM
$NTLA 100$ next year
0 · Reply
SevenClips
SevenClips Dec. 22 at 2:50 PM
$NTLA
0 · Reply
SevenClips
SevenClips Dec. 22 at 2:48 PM
$NTLA
0 · Reply
Elamenape2
Elamenape2 Dec. 22 at 2:28 PM
$CRSP $LLY New Info! New Partnership! Huge for the Gene Sector! 🧬 $PRME $NTLA
0 · Reply
VVDB
VVDB Dec. 21 at 3:46 PM
$NTLA Does anyone have update on the FDA hold? https://youtu.be/hwTSgFpWzQ8?si=DeKS1Xf67SimgrIs
0 · Reply